Skip to Content
  • Review
  • Open Access

22 May 2018

32 Pages

Melatonin as a Therapy for Traumatic Brain Injury: A Review of Published Evidence

,
,
,
,
,
,
and
1
School of Nursing, University of Texas at Austin, Holistic Adult Health, Austin, TX 78712, USA
2
Department of Neurology, Dell Medical School, University of Texas at Austin, Austin, TX 78705, USA
3
School of Nursing, University of Pittsburgh, Pittsburgh, PA 15213, USA
4
Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15260, USA

Abstract

Melatonin (MEL) is a hormone that is produced in the brain and is known to bind to MEL-specific receptors on neuronal membranes in several brain regions. MEL’s documented neuroprotective properties, low toxicity, and ability to cross the blood-brain-barrier have led to its evaluation for patients with traumatic brain injury (TBI), a condition for which there are currently no Food and Drug Administration (FDA)-approved therapies. The purpose of this manuscript is to summarize the evidence surrounding the use of melatonin after TBI, as well as identify existing gaps and future directions. To address this aim, a search of the literature was conducted using Pubmed, Google Scholar, and the Cochrane Database. In total, 239 unique articles were screened, and the 22 preclinical studies that met the a priori inclusion/exclusion criteria were summarized, including the study aims, sample (size, groups, species, strain, sex, age/weight), TBI model, therapeutic details (preparation, dose, route, duration), key findings, and conclusions. The evidence from these 22 studies was analyzed to draw comparisons across studies, identify remaining gaps, and suggest future directions. Taken together, the published evidence suggests that MEL has neuroprotective properties via a number of mechanisms with few toxic effects reported. Notably, available evidence is largely based on data from adult male rats and, to a lesser extent, mice. Few studies collected data beyond a few days of the initial injury, necessitating additional longer-term studies. Other future directions include diversification of samples to include female animals, pediatric and geriatric animals, and transgenic strains.

1. Introduction

Traumatic brain injury (TBI) affects countless individuals worldwide [1,2,3,4,5,6,7,8,9], with an estimated 2.5 million cases in the United States during 2010 alone [1]. Available treatments are not appreciably relieving symptoms and the quest for new therapies has not led to a single Food and Drug Administration (FDA)-approved therapy and, consequently, TBI patients often suffer long-term disabilities. Therefore, identifying novel TBI therapeutics that are safe and effective remains crucial.
One promising candidate is melatonin (MEL), a naturally occurring hormone that is also available as an over-the-counter dietary supplement. MEL possesses many of the fundamental characteristics of a central nervous system (CNS) therapeutic including low toxicity [10,11,12], an ability to cross the blood-brain-barrier [13,14,15], and receptors that bind MEL in the CNS [16,17,18,19]. While the therapeutic effects of MEL in human TBI remain understudied, MEL has demonstrated beneficial effects in pre-clinical models of several CNS disorders, including conditions with similar pathology and symptoms profiles, to TBI such as: Huntington’s disease [20], Alzheimer’s disease [21], amyotrophic lateral sclerosis [22,23], stroke [24,25], sepsis-induced brain dysfunction [21], and spinal cord injury [26,27]. In the aforementioned contexts, MEL reduces secondary injury (e.g., apoptosis, inflammation, and oxidative stress) as well as reduces symptoms and functional deficits (e.g., memory, learning, and motor) [21,26,27,28]. It is possible that in the context of TBI, MEL will have similar improvements in secondary injury pathways and reduce symptom burden, which may contribute to other beneficial outcomes such as earlier return to play for sports-related injuries.
There remains a significant gap in the literature pertaining to the role of therapeutic MEL after TBI due to direct injury to the brain or skull. Moreover, no recent review has comprehensively evaluated the TBI knowledge base as it pertains to MEL. The most comprehensive review available on this topic was published by Samantaray and colleagues in 2009, prior to publication of 13 of the articles included in this review. A more recent review of melatonin as a therapy for central nervous system injury was published by Naseem & Parvez (2014), but this review emphasizes spinal cord injury and cites only 4 TBI studies. The purpose of this review is to provide a comprehensive review which highlights the state-of-the-science as it pertains to the published evidence of pharmaceutical applications of MEL as a TBI therapy. Published evidence is summarized in tabular form, including sample (sample size, species, and characteristics), groups (number of groups, number of subjects per group; treatment of groups), results (outcomes and details regarding how and when they were assessed), conclusions, and limitations. This review will also identify gaps in the available evidence and suggest future directions for ongoing research.

2. Results

In total, more than 200 unique articles were identified using the key word searches, alone or in combination (n = 239). Of these, articles were further screened using the following exclusion criteria: (1) written in a language other than English; (2) tested a condition beyond traumatic injury directly to the brain or skull (e.g., stroke; sepsis-induced neurological deficits; chemically-induced injury); (3) did not test the effect of melatonin; or (4) did not use an in vivo model (e.g., neuronal stretch model or another in vitro model). After applying the aforementioned exclusion criteria, a total of 22 articles remained (See Table A1, Table A2, Table A3, Table A4, Table A5, Table A6, Table A7, Table A8, Table A9, Table A10, Table A11, Table A12, Table A13, Table A14, Table A15, Table A16, Table A17, Table A18, Table A19, Table A20, Table A21 and Table A22). The studies analyzed a variety of TBI conditions, ranging from mild (Table A7 and Table A21) to moderate (Table A3 and Table A17). The remainder of the studies did not specify the severity of the condition.
The global interest in evaluating the therapeutic effects of MEL after TBI is evident by the worldwide research conducted on this topic, including 8 studies from Turkey [20,24,29,30,31,32,33,34], 4 from the United States [35,36,37], 3 from China [38,39], 2 from Iran [40,41], 2 from Israel [42,43], 1 from France [44], 1 from Germany [44], and 1 from Italy [45].
The majority of the studies used rats, most commonly Sprague-Dawley rats [29,30,31,35,36,39,46,47,48] or Wistar rats [20,24,32,33]; N-Mary rats were used in 1 study [41] and NMRI rats used in another [40]. Less commonly, mice were used as the test animals, including the following strains: CD1 mice [39,45], Sabra mice [42], BALB/c [34], C57BL/6 mice [49,50], and Swiss mice [44]. Most of the studies conducted experiments on adult test animals with two exceptions testing the effects of childhood TBI [20,24]; one study did not specify the age of the test animals [33]. None of the studies explicitly included female mice in their sample, though some studies did not report the sex of the test animals [20,24,33,50].
Several different injury models were used to garner evidence regarding the therapeutic effects of MEL after TBI. Most commonly used was weight drop injury, which was employed in 12 of the studies [20,24,29,30,31,32,33,38,41,42,43,44]. Of the studies using weight drop, several methods and modifications were used including: Marmarou’s model, Feeney’s model, and Marklund’s model. The second most common method of inducing TBI in the MEL literature was controlled cortical impact (CCI), which was used in 6 studies [36,39,44,45,50,51]. Less commonly used models include surgical brain injury [35], fluid percussion injury [46], and cold-probe injury [34].
Most of the studies tested the effect of melatonin alone. Some of the studies tested multiple doses of MEL or several dosing schedules [20,24,33,35,39,40,41,48]. A small number of studies compared the effects of MEL to another drug with known neuroprotective (e.g., anti-oxidant) properties [20,42,43]. Five studies tested the effects of MEL in combination with another drug [34,38,45,46]. This evaluation of combination therapy has been suggested as a direction for future TBI researchers, since TBI pathophysiology is complex and may not be realistically targeted with a single drug [52].
Most of the studies tested the effects of MEL on cellular and histopathological outcomes, including but are not limited to: edema, markers of oxidative stress, inflammatory cytokines, lesion size, and mitophagy. Half of the studies tested the effect of MEL on one or more behavioral or functional outcomes after TBI [20,24,30,35,36,42,45]. The behavioral outcomes assessed in the studies included cognitive function assessed using the Morris water maze and motor function assessed using the Beam balance test, wire grip test, or a composite neuroscore.
While the therapeutic effects of MEL in human TBI remain understudied, some characterization of endogenous MEL after TBI has been published. One study [53] collected cerebrospinal fluid (CSF) and serum out to 13 days post-TBI and compared melatonin levels to that in controls who had a CSF sample collected during surgery for a condition distinct from TBI. CSF MEL fluctuated over time in a biphasic fashion, gradually increasing until day 2 post-TBI and then progressively decreasing to a minimum on day 5 with levels reaching a maximum on day 8. Overall, and for all days except of 0, 1, and 4, CSF MEL levels were significantly higher in TBI patients than controls. Serum MEL levels also increased from admission to day 2 post-TBI and then reached a minimum level on day 5; no significant differences in serum MEL levels between TBI patients and controls were reported [53]. A second study [54] examined MEL levels in the blood 8 times per day for the first two days after TBI but lacked a control group. MEL concentrations in the blood were lower than established clinical ranges and diurnal variation in MEL levels were associated with neurological outcomes assessed using the Glasgow Coma Scale (GCS); specifically, patients with lower GCS showed disrupted diurnal variation in MEL levels compared to those with higher GCS [54]. A third study [30] recruited TBI survivors 6 months after the initial diagnosis and compared their salivary MEL levels to non-TBI controls. Samples were collected under tight experimental controls including dim light (<10 lux), posture, and activity. Every half hour between 6:00 pm and 12:30 am participants provided saliva samples which were frozen at −20 °C until further analysis. When 14 TBI survivors and 14 controls were compared, there was no significant difference in dim light melatonin onset; however, when the total melatonin production over the entire sampling period was compared, significantly higher melatonin production (p = 0.031) occurred in controls [16]. Overall, the evidence suggests MEL levels go up then down in the acute period and may remain depressed chronically. Taken together, it is plausible that MEL is involved in the body’s response to TBI but may be inadequate for post-TBI neuroprotection [16,53,54].

Clinical Studies

While additional pre-clinical research is needed, effort to translate MEL to clinical trials has begun. Specifically, there is an ongoing clinical trial in Canada exploring the effects of therapeutic MEL after pediatric TBI [55]. The pilot work underlying this clinical trial used a retrospective chart review of 48 pediatric TBI patients being treated for post-traumatic headache. The authors found that 18 (37.5%) of the patients received MEL therapy, suggesting this drug is administered after TBI in some units, despite the lack of clinical trials and limited pre-clinical evidence. Of the 18 patients receiving MEL, 15 (83%) demonstrated a therapeutic response. Since this was a retrospective study, there was no control over therapeutic regimen: 7 patients received doses between 3–5 mg and 8 patients received a dose between 6–10 mg. The ongoing clinical trial entitled the Post-concussion Syndrome in Youth—Assessing the gamma-aminobutyric acid (GABA)-ergic Effects of Melatonin (PLAYGAME) study, which will build on these pilot findings using a randomized control trial. As of 18 April 2018, this study is still active, but has stopped recruiting; it was previously enrolling males and females, aged 8–19, with mild TBI. The study will test the effects of either 3 mg or 10 mg of MEL administered sublingually for 28 days after trauma on symptoms of post-concussion syndrome assessed using the Post-Concussion Inventory (PSCI) score for parents (PSCI-P) and youth (PSCI-Y), the child health questionnaire for both parents and children, the behavior assessment system, and the behavior rating inventory of executive function. In addition to the effects of each dose on outcomes, the authors will explore a possible dose-response effect, as well as whether the effect of treatment is independent of the effect of sleep. The proposed PLAYGAME TRIAL end date is November of 2019.
A second clinical trial [52] recruited 7 male TBI patients age 16–65 (average = 39.6 years) who had previously sustained a TBI and suffered a post-TBI history of sleep disturbance. All of the participants were fully oriented and none had a history of neurological insults or dependence on drugs and/or alcohol. Potential test subjects were excluded if they were taking amitriptyline, a drug administered during the study. In this study, a randomized double-blind controlled cross-over trial was used to compare the effects of two drugs: 5 mg of MEL or 25 mg of amitriptyline. In this study, the effects of drug therapy were modest; MEL improved daytime alertness but did not improve sleep latency, sleep duration, or sleep quality, nor did it improve mood-related measures or cognitive performance. Response bias is an issue in this study as self-reports were not entirely consistent with the diaries used in data collection. Additional studies testing the effects of MEL after TBI are needed.

3. Discussion

3.1. Summary

Taken together the pre-clinical evidence surrounding MEL remains conflicted. The majority of studies showed some beneficial effect of MEL using one or more dosing regimens; however, one study [38] found no beneficial effect of MEL. Moreover, some studies showed dose-response effects. Commonly, a bell-shaped curve was reported with the middle dose, conferring benefit, and low and high doses ineffective [43,44]. Notably, the effective doses differed, with one study finding 1.25 mg/kg of MEL (but not 0.625 mg/kg or 2.5 mg/kg) effective [44], and another study finding 5 mg/kg (not 1 mg/kg or 10 mg/kg) effective [43]. Moreover, some of the regimens studied actually compounded the deleterious effects of injury. In one study, a dose of 150 mg/kg of MEL worsened edema, lipid peroxidation, vibrissae stimulation study, beam balance performance, and composite neuroscore [35]. In a second study, a dose of 200 mg/kg of MEL increased lipid peroxidation [32]. Other studies tested more than one dose of MEL but did not report dose-dependent effects [40,42]. Further research is necessary to understanding these adverse effects, especially since doses that led to adverse effects in one study were associated with neuroprotection in other studies [32,44,46]. Moreover, five of the studies [34,39,45,46] tested the effects of MEL in combination with another drug and found the effects of combined therapy were superior to the effects of either drug alone; this is consistent with a growing body of evidence that two or more drugs in combination may be needed to adequately treat TBI [52]. All in all, the majority of the authors’ research supports the conclusion that the use of MEL as a method for treatment of TBI, if used under appropriate conditions at an appropriate dosage, can be beneficial. Taken together, the evidence is limited and requires replication and expansion of published findings.

3.2. Critical Analysis of Published Studies

Overall, the pre-clinical knowledge base is limited by the lack of a well-tested conceptual framework surrounding the neuroprotective mechanisms of MEL; this limitation affects the researcher’s ability to design studies and contributes to the inconsistent results in published studies. Additional research testing MEL as a potential therapeutic agent is necessary to support clinical trials and translational efforts. Traditionally, the beneficial effects of MEL within the CNS are attributed to its anti-oxidant capacity [10,11,12,13,14,56]. Anti-apoptotic effects of MEL have also been reported in the CNS [4,9,21,25,57], including after TBI [9,20,21,22,23,24,25,35,36,38,43,44,45]. One study found MEL therapy promoted mitophagy after TBI [47].
It is also worth noting that none of the studies reviewed acknowledged the role of endogenous MEL receptors, including MT1 and MT2, two MEL-specific receptors found in the mammalian brain [37,38]. This represents a limitation of the research since MEL receptor levels have been found to be reduced after TBI [57] and evidence from a mouse model of Huntington’s disease suggests the anti-apoptotic effects of MEL are MT1 receptor-dependent [21]. The role of MT1 and MT2 remains unclear in the context of TBI and may be relevant to personalized medicine since functional polymorphisms in MT1 have been identified [26,56].

3.3. Limitations and Methodological Inconsistencies of Published Studies

Examination of the existing body of literature has led to identification of a major limitation in TBI research; that being that most studies are limited to the acute effects of TBI assessed only within a few days of initial injury. Only four studies [3,20,24,32,47] examined outcomes at or beyond 2 weeks post-injury. Notably, the longest data-collection period of the studies included in this review was 3 weeks post-TBI [20,24]. Future studies will be strengthened by outcome assessment into the chronic period including studies collecting data beyond 3 weeks of the initial injury.
Another limitation in the existing evidence surrounds the type of test animals used. A lack of inclusion of female test animals represents a limitation of the existing knowledge base and an area for future research. While males are more likely to sustain a TBI in all age groups [9,58], female TBI remains a significant worldwide problem stemming from domestic violence as well as traditional injury mechanisms (e.g., motor vehicle accidents; falls). Still, this overrepresentation of males in experimental TBI studies represents a limitation of the evidence; notably, to address this common limitation, many research funding agencies are now requiring that studies include female test animals or sufficiently justify exclusion from the sample.
Similarly, there was an overrepresentation of adult test animals in the studies reviewed with only two studies [20,24] focusing specifically on juvenile animals and none focusing on aged or senescence-prone animals. Additional research using representative pre-clinical samples is necessary to promote high-quality evidence that is translatable to clinical trials and ultimately applicable to the TBI patient population. Regardless of the test animals used, it is critical that details pertaining to sex, age, strain, and weight be reported as consistent with the Common Data Elements (CDEs) published by the National Institute of Neurological Diseases and Stroke (NINDS) [59]. Not all of the studies reviewed adequately provided these details that would be necessary to replicate the research. Another detail that was occasionally omitted from the studies in this literature review was diet [33,44,47,48], though most studies specified that animals had ad libitum access to food and water.
An important consideration for studies examining the melatonergic system or testing how therapeutic MEL pertains to the light/dark cycles on which animals are maintained. The vast majority of studies summarized in this review housed animals on 12 h light/12 h dark cycles. One study kept animals on a 14 h light/10 h dark cycle [44], and two studies did not specify conditions [33,35]. Several studies provided additional details about the timing of experimental procedures [20,24,43]; this information may be relevant to replication efforts. One study empirically compared the effects of normal 12 h light/12 h dark cycles to constant darkness on TBI outcomes [30]. Notably, this study found that results differed depending on whether the animal was kept in constant darkness or not, which suggests that this information should be reported in publications and considered when planning experiments.

3.4. Directions for Future Research

Future research efforts are needed to replicate the effects in published studies. Efforts should focus on dosage optimization and exploration of why the same dose had differing effects across published studies. Efforts to increase generalizability of studies are also needed, such as inclusion of more female test animals as well as more diverse ages. Longer-term histological and behavioral data should be collected. Moreover, better characterization of endogenous changes in the melatonergic system including MEL-specific receptors is needed, both in pre-clinical and clinical studies. Additionally, retrospective comparisons of individuals who were taken melatonin supplements at the time of their injury to those who did not supplement are worth pursuing. Finally, completion of ongoing clinical trials is needed so that more avenues for refinement of the knowledge base can be identified and pursued.

3.5. Limitations in the Methodology Used in This Review

This review, while the most comprehensive of its kind, does have limitations worth noting. Most importantly, only articles originally published in English or with a published English translation were used, which means that important literature from international research teams may not have been included. Likewise, the gray literature (e.g., dissertations) was not searched. A further limitation is the fact that our methods, while rigorous, did not follow any formal guidelines for a systematic review (e.g., the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines).

4. Materials and Methods

Initial literature searches were conducted in October 2014 and January 2015; at that time, alerts were set to notify the authors of additional publications on the topic of interest. To ensure no new articles were missed, a second search of the literature was conducted in May 2016. During the primary search of the literature, the following web resources were searched: PubMed, PubMed Central, Google Scholar, and the Cochrane Database. The following search terms were used, alone or in combination: traumatic brain injury, TBI, brain injury, head injury, experimental brain injury, Melatonin, MEL, and pineal. Secondary searches were executed using bibliographies from articles identified in the primary search.

5. Conclusions

There are few studies testing MEL therapy after TBI and, with the exception of two clinical trials [52,56], are limited to preclinical models. The results of the 22 pre-clinical studies identified varied, though most found a beneficial effect of MEL at one or more of the dosing regimens trialed. The studies summarized in this review were characterized by variations in the therapeutic regimen (e.g., dose, timing), and outcome variables chosen were largely limited to acute evaluation of cellular and histopathological outcomes. Taken together, the evidence suggests that MEL is a safe and low-toxic drug with neuroprotective properties after TBI. Future studies need to expand the pre-clinical samples to enhance generalizability, as well as examine longer-term histopathological and behavioral outcomes.

Author Contributions

N.O. conceptualized and drafted the manuscript, along with coordinating coauthors. E.M. edited the working draft and assisted in formatting the final product of the paper. L.P. completed the table and assisted in writing and editing the draft. The other coauthors made significant contributions to the conceptualization and outlining, along with providing extensive feedback that guided the development and refinement of the manuscript.

Funding

This work was supported by the National Institutes of Health (T32NR009759, F31NR014957). The Pittsburgh Foundation (Copeland Awards); the International Society of Nurses in Genetics; The Neurotrauma Nursing Foundation/American Association of Neuroscience Nursing; and Sigma Theta Tau International Eta Chapter.

Acknowledgments

The authors would like to thank Michael Farmer and Marilyn Farmer for their continued editorial support.

Conflicts of Interest

The authors declare no conflicts of interest.

Appendix A

Table A1. Mésenge et al. (1998) Study Details.
Table A2. Cirak et al. (1999) Study Details.
Table A3. Sarrafzadeh et al. (2000) Study Details.
Table A4. Beni et al. (2004) Study Details.
Table A5. Ozdemir et al. (2005) Study Details.
Table A6. Ozdemir et al. (2005) Study Details.
Table A7. Ucar et al. (2005) Study Details.
Table A8. Ates et al. (2006) Study Details.
Table A9. Jadha et al. (2009) Study Details.
Table A10. Kabadi et al. (2010) Study Details.
Table A11. Kelso et al. (2011) Study Details.
Table A12. Dehghan et al. (2013) Study Details.
Table A13. Campolo et al. (2013) Study Details.
Table A14. Senol et al. (2014) Study Details.
Table A15. Yürüker et al. (2015) Study Details.
Table A16. Ding et al. (2015) Study Details.
Table A17. Babaee et al. (2015) Study Details.
Table A18. Shochat et al. (2015) Study Details.
Table A19. Kelestemur et al. (2016) Study Details.
Table A20. Lin et al. (2016) Study Details.
Table A21. Alluri et al. (2016) Study Details.
Table A22. Wu et al. (2016) Study Details.

References

  1. Centers for Disease Control and Prevention. CDC—Statistics—Traumatic Brain Injury—Injury Center. 2013. Available online: http://www.cdc.gov/traumaticbraininjury/statistics.html (accessed on 8 May 2018).
  2. Colantonio, A.; Saverino, C.; Zagorski, B.; Swaine, B.; Lewko, J.; Jaglal, S.; Vernich, L. Hospitalizations and emergency department visits for TBI in Ontario. Can. J. Neurol. Sci. 2010, 37, 783–790. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Faul, M.; Xu, L.; Wald, M.M.; Coronado, V.G. Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations, and Deaths. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. 2010. Available online: http://www.cdc.gov/traumaticbraininjury/pdf/blue_book.pdf (accessed on 8 May 2018).
  4. Feigin, V.L.; Theadom, A.; Barker-Collo, S.; Starkey, N.J.; McPherson, K.; Kahan, M.; Dowell, A.; Brown, P.; Parag, V.; Kydd, R. Incidence of traumatic brain injury in New Zealand: A population-based study. Lancet Neurol. 2013, 12, 53–64. [Google Scholar] [CrossRef] [Scilit]
  5. Puvanachandra, P.; Hyder, A. Traumatic brain injury in Latin America and the Caribbean: A call for research. Salud Pública de México 2008, 50, 13–15. [Google Scholar] [CrossRef] [Scilit]
  6. Reilly, P. The impact of neurotrauma on society: An international perspective. Prog. Brain Res. 2007, 161, 3–9. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  7. Roozenbeek, B.; Maas, A.I.R.; Menon, D.K. Changing patterns in the epidemiology of traumatic brain injury. Nat. Rev. Neurol. 2013, 9, 231–236. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  8. Scudellari, M. Brain, Interrupted. Scientist 2010, 24, 36–41. [Google Scholar]
  9. Coronado, V.G.; McGuire, L.C.; Faul, M. Sugarman, Pearson; The Epidemiology and Prevention of TBI: Atlanta, GA, USA, 2012.
  10. Wang, X. The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci. Ther. 2009, 15, 345–357. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  11. Jahnke, G.; Marr, M.; Myers, C.; Wilson, R.; Travlos, G.; Price, C. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol. Sci. 1999, 50, 271–279. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  12. Seabra, M.L.; Bignotto, M.; Pinto, L.R.; Tufik, S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J. Pineal Res. 2000, 29, 193–200. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. Weaver, D.; Rivkees, S.; Reppert, S. Localization and characterization of melatonin receptors in rodent brain by in vitro autoradiography. J. Neurosci. 1989, 9, 2581–2590. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  14. Di Bella, L.; Gualano, L. Key aspects of melatonin physiology: Thirty years of research. Neuro Endocrinol. Lett. 2006, 27, 425–432. [Google Scholar] [PubMed]
  15. Le Bars, D.; Thivolle, P.; Vitte, P.A.; Bojkowski, C.; Chazot, G.; Arendt, J.; Frackowiak, R.S.J.; Claustrat, B. PET and plasma pharmacokinetic studies after bolus intravenous administration of 11C-melatonin in humans. Int. J. Radiat. Appl. Instrum. Part B Nucl. Med. Biol. 1991, 18, 357–362. [Google Scholar] [CrossRef] [Scilit]
  16. Shekleton, J.A.; Parcell, D.L.; Redman, J.R.; Phipps-Nelson, J.; Ponsford, J.L.; Rajaratnam, S.M.W. Sleep disturbance and melatonin levels following traumatic brain injury. Neurology 2010, 74, 1732–1738. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  17. Naseem, M.; Parvez, S. Role of melatonin in traumatic brain injury and spinal cord injury. Sci. World J. 2014, 2014, 586270. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. Srinivasan, V. Melatonin oxidative stress and neurodegenerative diseases. Indian J. Exp. Biol. 2002, 40, 668–679. [Google Scholar] [PubMed]
  19. Wiechmann, A.F.; Chignell, C.F.; Roberts, J.E. Influence of dietary melatonin on photoreceptor survival in the rat retina: An ocular toxicity study. Exp. Eye Res. 2008, 86, 241–250. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  20. Ozdemir, D.; Uysal, N.; Gonenc, S.; Acikgoz, O.; Sonmez, A.; Topcu, A.; Ozdemir, N.; Duman, M.; Semin, I.; Ozkan, H. Effect of melatonin on brain oxidative damage induced by traumatic brain injury in immature rats. Physiol. Res. 2005, 54, 631–637. [Google Scholar] [PubMed]
  21. Wang, X.; Sirianni, A.; Pei, Z.; Cormier, K.; Smith, K.; Jiang, J.; Zhou, S.; Wang, H.; Zhao, R.; Yano, H.; et al. The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. J. Neurosci.  2011, 31, 14496–14507. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  22. Asayama, K.; Yamadera, H.; Ito, T.; Suzuki, H.; Kudo, Y.; Endo, S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J. Nippon Med. Sch. 2003, 70, 334–341. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. Weishaupt, J.H.; Bartels, C.; Pölking, E.; Dietrich, J.; Rohde, G.; Poeggeler, B.; Mertens, N.; Sperling, S.; Bohn, M.; Hüther, G.; et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J. Pineal Res. 2006, 41, 313–323. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  24. Ozdemir, D.; Tugyan, K.; Uysal, N.; Sonmez, U.; Sonmez, A.; Acikgoz, O.; Ozdemir, N.; Duman, M.; Ozkan, H. Protective effect of melatonin against head trauma-induced hippocampal damage and spatial memory deficits in immature rats. Neurosci. Lett. 2005, 385, 234–239. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  25. Zhang, Y.; Cook, A.; Kim, J.; Baranov, S.V.; Jiang, J.; Smith, K.; Cormier, K.; Bennett, E.; Browser, R.P.; Day, A.L.; et al. Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2013, 55, 26–35. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  26. Wang, J.; Xiao, X.; Zhang, Y.; Shi, D.; Chen, W.; Fu, L.; Xie, F.; Kang, T.; Huang, W.; Deng, W. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J. Pineal Res. 2012, 53, 77–90. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  27. Olcese, J.M.; Cao, C.; Mori, T.; Mamcarz, M.B.; Maxwell, A.; Runfeldt, M.J.; Wang, L.; Zhang, C.; Lin, X.; Zhang, G.; et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J. Pineal Res. 2009, 47, 82–96. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  28. Samantaray, S.; Sribnick, E.A.; Das, A.; Knaryan, V.H.; Matzelle, D.D.; Yallapragada, A.V.; Reiter, R.J.; Ray, S.K.; Banik, N.L. Melatonin attenuates calpain upregulation, axonal damage and neuronal death in spinal cord injury in rats. J. Pineal Res. 2008, 44, 348–357. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  29. Senol, N.; Nazıroğlu, M. Melatonin reduces traumatic brain injury-induced oxidative stress in the cerebral cortex and blood of rats. Neural Regener. Res. 2014, 9, 1112–1116. [Google Scholar] [CrossRef] [Scilit]
  30. Ucar, T.; Ozkaya, G.; Demir, N.; Gurer, I.; Akyuz, M.; Onal, M.Z. The effects of environmental light–dark changes on experimental mild traumatic brain injury. Acta Neurol. Scand. 2005, 112, 163–172. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  31. Yürüker, V.; Naz, M.; Nilgün, Ş. Reduction in traumatic brain injury-induced oxidative stress, apoptosis, and calcium entry in rat hippocampus by melatonin: Possible involvement of TRPM2 channels. Metab. Brain Dis. 2015, 30, 223–231. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  32. Ates, O.; Cayli, S.; Gurses, I.; Yucel, N.; Iraz, M.; Altinoz, E.; Kocak, A.; Yologlu, S. Effect of pinealectomy and melatonin replacement on morphological and biochemical recovery after traumatic brain injury. Int. J. Dev. Neurosci. 2006, 24, 357–363. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  33. Cirak, B.; Rousan, N.; Kocak, A.; Palaoglu, O.; Palaoglu, S.; Kilic, K. Melatonin as a free radical scavenger in experimental head trauma. Pediatr. Neurosurg. 1999, 31, 298–301. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  34. Kelestemur, T.; Yulug, B.; Caglayan, A.B.; Beker, M.C.; Kilic, U.; Caglayan, B.; Yalcin, E.; Gundogdu, R.Z.; Kilic, E. Targeting different pathophysiological events after traumatic brain injury in mice: Role of melatonin and memantine. Neurosci. Lett. 2016, 612, 92–97. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  35. Jadhav, V.; Lee, S.; Ayer, R.E.; Rojas, H.; Hyong, A.; Lekic, T.; Tang, J.; Zhang, J.H. Dual effects of melatonin on oxidative stress after surgical brain injury in rats. J. Pineal Res. 2009, 46, 43–48. [Google Scholar] [CrossRef] [Scilit]
  36. Kelso, M.L.; Scheff, N.N.; Scheff, S.W.; Pauly, J.R. Melatonin and minocycline for combinatorial therapy to improve functional and histopathological deficits following traumatic brain injury. Neurosci. Lett. 2011, 488, 60–64. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  37. Liu, J.-B.; Tang, T.-S.; Yang, H.-L.; Xiao, D.-S. Antioxidation of melatonin against spinal cord injury in rats. Chin. Med. J. 2004, 117, 571–575. [Google Scholar] [PubMed]
  38. Ding, K.; Xu, J.; Wang, H.; Zhang, L.; Wu, Y.; Li, T. Melatonin protects the brain from apoptosis by enhancement of autophagy after traumatic brain injury in mice. Neurochem. Int. 2015, 91, 46–54. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  39. Lin, C.; Chao, H.; Li, Z.; Xu, X.; Liu, Y.; Hou, L.; Liu, N.; Ji, J. Melatonin Attenuates Traumatic Brain Injury-induced Inflammation: A Possible Role for Mitophagy. J. Pineal Res. 2016, 61, 177–186. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  40. Babaee, A.; Eftekhar-Vaghefi, S.H.; Asadi-Shekaari, M.; Shahrokhi, N.; Soltani, S.D.; Malekpour-Afshar, R.; Basiri, M. Melatonin treatment reduces astrogliosis and apoptosis in rats with traumatic brain injury. Iran. J. Basic Med. Sci. 2015, 18, 867–872. [Google Scholar] [PubMed]
  41. Dehghan, F.; Khaksari Hadad, M.; Asadikram, G.; Najafipour, H.; Shahrokhi, N. Effect of melatonin on intracranial pressure and brain edema following traumatic brain injury: Role of oxidative stresses. Arch. Med. Res. 2013, 44, 251–258. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  42. Beni, S.M.; Kohen, R.; Reiter, R.J.; Tan, D.-X.; Shohami, E. Melatonin-induced neuroprotection after closed head injury is associated with increased brain antioxidants and attenuated late-phase activation of NF-κB and AP-1. FASEB J. 2004, 18, 149–151. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  43. Shochat, A.; Abookasis, D. Differential effects of early postinjury treatment with neuroprotective drugs in a mouse model using diffuse reflectance spectroscopy. Neurophotonics 2015, 2, 015001. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  44. Mesenge, C.; Margaill, I.; Verrecchia, C.; Allix, M.; Boulu, R.G.; Plotkine, M. Protective effect of melatonin in a model of traumatic brain injury in mice. J. Pineal Res. 1998, 25, 41–46. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  45. Campolo, M.; Ahmad, A.; Crupi, R.; Impellizzeri, D.; Morabito, R.; Esposito, E.; Cuzzocrea, S. Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury. J. Endocrinol. 2013, 217, 291–301. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  46. Kabadi, S.V.; Maher, T.J. Posttreatment with uridine and melatonin following traumatic brain injury reduces edema in various brain regions in rats. Ann. N. Y. Acad. Sci. 2010, 1199, 105–113. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  47. Wu, H.; Shao, A.; Zhao, M.; Chen, S.; Yu, J.; Zhou, J.; Liang, F.; Shi, L.; Dixon, B.J.; Wang, Z.; et al. Melatonin attenuates neuronal apoptosis through up-regulation of K+–Cl− Cotransporter KCC2 expression following traumatic brain injury in rats. J. Pineal Res. 2016. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  48. Sarrafzadeh, A.S.; Thomale, U.W.; Kroppenstedt, S.N.; Unterberg, A.W. Neuroprotective effect of melatonin on cortical impact injury in the rat. Acta Neurochir. 2000, 142, 1293–1299. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  49. Zhao, L.; Liu, H.; Yue, L.; Zhang, J.; Li, X.; Wang, B.; Lin, Y.; Qu, Y. Melatonin Attenuates Early Brain Injury via the Melatonin Receptor/Sirt1/NF-κB Signaling Pathway Following Subarachnoid Hemorrhage in Mice. Mol. Neurobiol. 2016, 54, 1612–1621. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  50. Alluri, H.; Wilson, R.L.; Anasooya Shaji, C.; Wiggins-Dohlvik, K.; Patel, S.; Liu, Y.; Peng, X.; Beeram, M.R.; Davis, M.L.; Huang, J.H.; et al. Melatonin Preserves Blood-Brain Barrier Integrity and Permeability via Matrix Metalloproteinase-9 Inhibition. PLoS ONE 2016, 11, e0154427. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  51. Huether, G. The contribution of extrapineal sites of melatonin synthesis to circulating melatonin levels in higher vertebrates. Experientia 1993, 49, 665–670. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  52. Kemp, S.; Biswas, R.; Neumann, V.; Coughlan, A. The value of melatonin for sleep disorders occurring post-head injury: A pilot RCT. Brain Inj. 2004, 18, 911–919. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  53. Seifman, M.A.; Adamides, A.A.; Nguyen, P.N.; Vallance, S.A.; Cooper, D.J.; Kossmann, T.; Rosenfeld, J.V.; Morganti-Kossmann, M.C. Endogenous melatonin increases in cerebrospinal fluid of patients after severe traumatic brain injury and correlates with oxidative stress and metabolic disarray. J. Cereb. Blood Flow Metab. 2008, 28, 684–696. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  54. Paparrigopoulos, T.; Melissaki, A.; Tsekou, H.; Efthymiou, A.; Kribeni, G.; Baziotis, N.; Geronikola, X. Melatonin secretion after head injury: A pilot study. Brain Inj. 2006, 20, 873–878. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  55. Barlow, K.M.; Brooks, B.L.; MacMaster, F.P.; Kirton, A.; Seeger, T.; Esser, M.; Crawford, S.; Nettel-Aguirre, A.; Zemek, R.; Angelo, M.; et al. A double-blind, placebo-controlled intervention trial of 3 and 10 mg sublingual melatonin for post-concussion syndrome in youths (PLAYGAME): Study protocol for a randomized controlled trial. Trials 2014, 15, 271. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  56. Onur, R.; Semerciöz, A.; Orhan, I.; Yekeler, H. The effects of melatonin and the antioxidant defence system on apoptosis regulator proteins (Bax and Bcl-2) in experimentally induced varicocele. Urol. Res. 2004, 32, 204–208. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  57. Alonso-Alconada, D.; Alvarez, A.; Lacalle, J.; Hilario, E. Histological study of the protective effect of melatonin on neural cells after neonatal hypoxia-ischemia. Histol. Histopathol. 2012, 27, 771–783. [Google Scholar] [PubMed]
  58. Centers for Disease Control and Prevention. Traumatic Brain Injury in the United States: Emergency Department Visits, Hospializationns, and Deaths 2002–2006; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2010.
  59. Smith, D.H.; Hicks, R.R.; Johnson, V.E.; Bergstrom, D.A.; Cummings, D.M.; Noble, L.J.; Hovda, D.; Whalen, M.; Ahlers, S.T.; LaPlaca, M.; et al. Pre-Clinical Traumatic Brain Injury Common Data Elements: Toward a Common Language Across Laboratories. J. Neurotrauma 2015, 32, 1725–1735. [Google Scholar] [CrossRef] [Scilit] [PubMed]

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.